<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28029010</article-id>
      <article-id pub-id-type="pmc">5204001</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2017.37.2.177</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group subj-group-type="subheading">
            <subject>Diagnostic Genetics</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Concomitant <italic>AID</italic> Expression and <italic>BCL7A</italic> Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Nae</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="author-notes" rid="FN1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shin</surname>
            <given-names>Saeam</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="author-notes" rid="FN1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Choi</surname>
            <given-names>Jong Rak</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Yoonjung</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lee</surname>
            <given-names>Kyung-A</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Laboratory Medicine, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Korea.</aff>
      <aff id="A3"><label>3</label>Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.</aff>
      <author-notes>
        <corresp>Corresponding author: Kyung-A Lee. Department of Laboratory Medicine, Yonsei University College of Medicine 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea. Tel: +82-2-2019-3531, Fax: +82-2-2019-4822, <email>KAL1119@yuhs.ac</email></corresp>
        <fn id="FN1" fn-type="equal">
          <p><sup>*</sup>N.Y. and S.S. contributed equally to this study.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <volume>37</volume>
      <issue>2</issue>
      <fpage>177</fpage>
      <lpage>179</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>7</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>08</day>
          <month>8</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>12</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2017</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <funding-group>
        <award-group>
          <funding-source country="KR">
            <institution-wrap>
              <institution>Ministry of Health and Welfare</institution>
              <institution-id institution-id-type="CrossRef">http://dx.doi.org/10.13039/501100003625</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>A120030</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <p>Dear Editor,</p>
    <p>The mechanisms involved in chronic myeloid leukemia (CML) progression from the chronic phase (CP) to an accelerated phase (AP) or blast crisis (BC) remain largely undetermined, but generally involve additional molecular changes besides the Philadelphia chromosome [<xref rid="B1" ref-type="bibr">1</xref>]. Evidence suggests that secondary <italic>BCR</italic> (breakpoint cluster region)-<italic>ABL1</italic> (Abelson murine leukemia viral oncogene homolog 1)-dependent/independent genetic events play a critical role in blast transformation [<xref rid="B2" ref-type="bibr">2</xref>]. Besides <italic>BCR-ABL1</italic> point mutations, deletions and/or rearrangements of other cancer-related genes have been associated with CML-BC [<xref rid="B2" ref-type="bibr">2</xref>]. Recent studies have demonstrated that aberrant activation-induced cytidine deaminase (<italic>AID</italic>) expression promotes genetic instability, eventually leading to progression and drug resistance in CML [<xref rid="B3" ref-type="bibr">3</xref>].</p>
    <p>We report a patient with a rare chromosomal translocation 46,XY,t(5;12)(p13;p13) that disrupts <italic>AID</italic> and causes a concomitant deletion of the tumor suppressor gene <italic>BCL7A</italic> (B-cell CLL/lymphoma 7A). This report presents evidence of a mechanism underlying CML progression and tyrosine kinase inhibitor (TKI) resistance occurring through an interaction between <italic>AID</italic> expression and <italic>BCL7A</italic> loss in a <italic>BCR-ABL1</italic> kinase domain mutation-independent manner.</p>
    <p>A 57-yr-old man presented in December 2010 with generalized weakness and chest pain. Bone marrow (BM) demonstrated nearly packed marrow owing to myeloid and megakaryocyte hyperplasia (blasts [0.4%]). Written informed consent for genetic analysis was obtained from the patient according to the ethical guidance of the institutional review board. The patient exhibited the b3a2 type <italic>BCR-ABL1</italic> fusion transcript, and cytogenetic analysis revealed a normal karyotype. The patient was diagnosed as having CML-CP and treated with imatinib (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
    <p>Sixteen months following diagnosis, treatment was replaced by dasatinib since <italic>BCR-ABL1</italic> transcripts had not declined. Simultaneously, one of 25 metaphase cells exhibited an abnormal karyotype of 46,XY,t(5;12)(p13;p13) (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). FISH analysis using a <italic>TEL/AML1</italic> translocation probe presented a normal result; therefore, another gene on chromosome 12p13 was suspected to be involved. Subsequent FISH analysis revealed a break in the <italic>AID</italic> signal on one allele in 12.2% of interphase cells using a custom-labeled probe (Empire Genomics LLC, Buffalo, NY, USA) (<xref ref-type="fig" rid="F1">Fig. 1B</xref>) compared with 0.2% of normal control cells. Quantitative analysis showed that <italic>AID</italic> RNA expression increased, whereas normal cells showed no <italic>AID</italic> expression.</p>
    <p>Chromosomal microarray using a CytoScan 750K Array (Affymetrix Inc., Santa Clara, CA, USA) revealed a 1.9-Mb deletion mostly containing <italic>BCL7A</italic> on chromosome 12q24.31 (<xref ref-type="fig" rid="F1">Fig. 1C</xref>).</p>
    <p>After 28 months, the patient progressed to CML-AP, and the CBC showed leukocyte counts of 116.8&#xD7;10<sup>9</sup>/L and 13% blasts. <italic>BCR-ABL1</italic> kinase domain sequencing revealed no mutation. Conversely, chromosomal abnormality of t(5;12)(p13;p13) exhibited clonal expansion. Thus, the patient was returned to imatinib therapy and subsequently demonstrated a complete hematologic response; however, <italic>AID</italic> breakage and <italic>BCR-ABL1</italic> transcript levels remained detectable.</p>
    <p>After 37 months, the patient presented again with CML-AP, with 13.5% blasts in peripheral blood, and karyotyping showed 46,XY,t(5;12)(p13;p13)[6]/46,XY[14]. The patient received allogeneic stem cell transplantation and achieved complete donor hematopoietic chimerism.</p>
    <p>The <italic>AID</italic> gene, located on chromosome 12p13, is associated with genomic instability and ensuing oncogenesis in various human malignancies including CML, AML, and ALL [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref>]. <italic>AID</italic> has several non-immunoglobulin targets, including <italic>PAX5</italic> and <italic>BCL7A</italic> [<xref rid="B3" ref-type="bibr">3</xref><xref rid="B6" ref-type="bibr">6</xref>]; <italic>PAX5</italic> can induce TKI resistance and CML progression via <italic>AID</italic> upregulation [<xref rid="B3" ref-type="bibr">3</xref>].</p>
    <p>Recently, it was shown that <italic>AID</italic> activation can induce mutations and translocations at the <italic>BCL7A</italic> locus [<xref rid="B6" ref-type="bibr">6</xref>]. <italic>BCL7A</italic> belongs to the BCL7 family, which includes <italic>BCL7B</italic> and <italic>BCL7C</italic>, and is a known pro-apoptotic tumor suppressor in B-cell oncogenesis. Specifically, BCL7B suppresses &#x3B2;-catenin expression, causing Wnt signaling inhibition [<xref rid="B7" ref-type="bibr">7</xref>]. Importantly, &#x3B2;-catenin deregulation in Wnt signaling is associated with genomic instability that can induce oncogenic translocations in T-cell lymphoma and AML [<xref rid="B5" ref-type="bibr">5</xref><xref rid="B8" ref-type="bibr">8</xref>]. In CML, &#x3B2;-catenin activation is observed in the AP or BC, and is believed to promote leukemic stem cell generation that facilitates disease progression [<xref rid="B9" ref-type="bibr">9</xref>].</p>
    <p>We suggest a novel pathway for disease progression and drug resistance in CML via <italic>AID</italic> expression and the concomitant loss of <italic>BCL7A</italic>. Our case supports the hypothesis that <italic>BCL7A</italic> deletion induces abnormal Wnt/&#x3B2;-catenin signaling, enhancing the potential for a chromosomal aberration and its persistence in our patient [<xref rid="B5" ref-type="bibr">5</xref><xref rid="B10" ref-type="bibr">10</xref>]. Loss of the tumor suppressor <italic>BCL7A</italic> may cooperate with <italic>AID</italic> activity in disease progression by causing aberrant cell cycle regulation [<xref rid="B1" ref-type="bibr">1</xref>]. Moreover, <italic>AID</italic>-induced DNA damage checkpoint activation causes initiation of tumor suppressor genes involved in DNA repair or cell cycle control [<xref rid="B1" ref-type="bibr">1</xref>]. A previous study showed that decreased tumor suppressor gene expression can cause <italic>AID</italic>-induced translocation, eventually leading to cancer [<xref rid="B10" ref-type="bibr">10</xref>].</p>
    <p>In conclusion, our report identifies that <italic>AID</italic>, in combination with <italic>BCL7A</italic>, likely confers TKI resistance in a <italic>BCR-ABL1</italic> kinase domain mutation-independent manner and may be a putative functional target in CML therapy.</p>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported by a grant from the Korean Health Technology Research and Development Project (A120030), Ministry of Health and Welfare, Republic of Korea.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement">
        <p><bold>Authors' Disclosures of Potential Conflicts of Interest:</bold> No potential conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strout</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Schatz</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way</article-title>
          <source>Cancer Cell</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>174</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="pmid">19732715</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neviani</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Genetic events other than BCR-ABL1</article-title>
          <source>Curr Hematol Malig Rep</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>24</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="pmid">24407376</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klemm</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Duy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Iacobucci</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kuchen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>von Levetzow</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Feldhahn</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia</article-title>
          <source>Cancer Cell</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>232</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="pmid">19732723</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feldhahn</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Henke</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Melchior</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Duy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Soh</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells</article-title>
          <source>J Exp Med</source>
          <year>2007</year>
          <volume>204</volume>
          <fpage>1157</fpage>
          <lpage>1166</lpage>
          <pub-id pub-id-type="pmid">17485517</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ugarte</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Medina</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Le&#xF3;n</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Necu&#xF1;ir</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Elorza</surname>
              <given-names>AA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Wnt signaling induces transcription, spatial proximity, and translocation of fusion gene partners in human hematopoietic cells</article-title>
          <source>Blood</source>
          <year>2015</year>
          <volume>126</volume>
          <fpage>1785</fpage>
          <lpage>1789</lpage>
          <pub-id pub-id-type="pmid">26333776</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kato</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Begum</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Burroughs</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Doi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Daub</surname>
              <given-names>CO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2012</year>
          <volume>109</volume>
          <fpage>2479</fpage>
          <lpage>2484</lpage>
          <pub-id pub-id-type="pmid">22308462</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uehara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kage-Nakadai</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yoshina</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Imae</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mitani</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The tumor suppressor BCL7B functions in the Wnt signaling pathway</article-title>
          <source>PLoS Genet</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>e1004921</fpage>
          <pub-id pub-id-type="pmid">25569233</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dose</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Emmanuel</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Chaumeil</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Germar</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>&#x3B2;-Catenin induces T-cell transformation by promoting genomic instability</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2014</year>
          <volume>111</volume>
          <fpage>391</fpage>
          <lpage>396</lpage>
          <pub-id pub-id-type="pmid">24371308</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jamieson</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Ailles</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Dylla</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Muijtjens</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zehnder</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>351</volume>
          <fpage>657</fpage>
          <lpage>667</lpage>
          <pub-id pub-id-type="pmid">15306667</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramiro</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Jankovic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Callen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Difilippantonio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>McBride</surname>
              <given-names>KM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of genomic instability and p53 in AID-induced c-myc-Igh translocations</article-title>
          <source>Nature</source>
          <year>2006</year>
          <volume>440</volume>
          <fpage>105</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">16400328</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <title>Genetic analysis of CML-AP BM samples. (A) Translocation site in G-banded karyotyping of the 46,XY,t(5;12)(p13;p13) (arrows). (B) Interphase FISH confirming three signals of the <italic>AID</italic> probe (red), resulting from <italic>AID</italic> rearrangement at the 12p13 locus. (4,6-diamidino-2-phenylindole stain, &#xD7;1,000). (C) Chromosomal microarray revealing copy number loss in the chromosome 12q24.31 region (arrow). Blue dots with a log2 transformed value of -1 represent a 1:2 copy number ratio to the reference genomic DNA, indicating a heterozygous deletion. The expansion view of the 12q24 region reveals a 1.9-Mb heterozygous interstitial deletion in chromosome 12 (121,949,449-123,968,599; hg19) that includes the <italic>BCL7A</italic> gene.</title>
        <p>Abbreviations: AP, accelerated phase; BM, bone marrow; <italic>AID</italic>, activation-induced cytidine deaminase; <italic>BCL7A</italic>, B-cell CLL/lymphoma 7A.</p>
      </caption>
      <graphic xlink:href="alm-37-177-g001"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <title>The clinical course of the patient</title>
      </caption>
      <alternatives>
        <graphic xlink:href="alm-37-177-i001"/>
        <table frame="hsides" rules="rows">
          <col width="19.12%" span="1"/>
          <col width="6.03%" span="1"/>
          <col width="6.03%" span="1"/>
          <col width="6.03%" span="1"/>
          <col width="9.12%" span="1"/>
          <col width="6.03%" span="1"/>
          <col width="9.12%" span="1"/>
          <col width="6.03%" span="1"/>
          <col width="6.03%" span="1"/>
          <col width="9.71%" span="1"/>
          <col width="7.79%" span="1"/>
          <col width="8.97%" span="1"/>
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">Time (months after diagnosis)</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">0</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">3</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">12</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">16</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">23</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">28</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">29</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">32</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">37</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">38</th>
              <th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(218,227,244)">46</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Diagnosis</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CML-CP</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CHR</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CHR</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CML-AP</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CHR</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">CML-AP</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Mixed donor chimerism</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Complete donor chimerism</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Karyotype</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">46,XY,t(5;12) (p13;p13) [<xref rid="B1" ref-type="bibr">1</xref>]/46,XY[24]</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">46,XY,t(5;12) (p13;p13) [<xref rid="B5" ref-type="bibr">5</xref>]/46,XY[15]</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">46,XY,t(5;12) (p13;p13) [<xref rid="B6" ref-type="bibr">6</xref>]/46,XY[14]</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1"><italic>BCR-ABL1</italic> transcript (relative ratio of <italic>BCR-ABL1</italic> to <italic>ABL1</italic>)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.00352</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.08</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.03</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.03</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.09<sup>*</sup></td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.089</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.000223</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Interphase FISH (% of <italic>AID</italic> rearrangement)</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">12.2</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">9.5</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">9.8</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1"><italic>AID</italic> mRNA expression (relative ratio of <italic>AID</italic> to <italic>ACTB</italic>)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.53</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.23</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5.32</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)"><italic>BCL7A</italic> copy number changes</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Normal</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">Deletion</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(238,242,249)">-</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Treatment</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Imatinib</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Dasatinib</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Nilotinib</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Imatinib</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">Allogeneic PBSCT</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
              <td valign="top" align="center" rowspan="1" colspan="1">-</td>
            </tr>
          </tbody>
        </table>
      </alternatives>
      <table-wrap-foot>
        <fn>
          <p><sup>*</sup>The real-time PCR method changed from LightCycler t(9;22) Quantification (Roche Molecular Systems, Branchburg, NJ, USA) to Real-Q <italic>BCR-ABL1</italic> Quantification (BioSewoom, Seoul, Korea) at the six month follow-up.</p>
          <p>Abbreviations: BM, bone marrow; CHR, complete hematologic response; AP, accelerated phase; CP, chronic phase; AID, activation-induced cytidine deaminase; PBSCT, peripheral blood stem cell transplantation.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
